Key Points. An abnormal venous calf muscle pump in the legs as measured by venous plethysmography is a risk factor for first VTE.rCPF unilaterally or bilaterall
In this issue of Blood, Murtadha et al demonstrate the efficacy of a new CD38-targeting immunotherapy for acute myeloid leukemia (AML).1
A single-chain CD38 T-cell engager targets CD38-negative LSCs activated by IFN-γ and induces CD38 expression on AML blasts.CD38 T-cell engager activates T
SLE occurs in 22% of children with ANA-associated AIC.Children of age >10 years and ANA titer >1/160 must be monitored long-term, for progression to
Although outcomes of various hematological diseases are improving, disparities continue to impact patients’ access to and outcomes following care. This
Blood Advances | 8 | 8 | April 2024
A single-chain CD38 T-cell engager targets CD38-negative LSCs activated by IFN-γ and induces CD38 expression on AML blasts.CD38 T-cell engager activates T
Different from “7 + 3” combination, CPX-351 prevents mucosal damage, dysbiosis, and morbidity in intestinal inflammation.CPX-351 protects via the aryl hydr
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
Key Points. Quantification of the primary myeloma cell surface proteome enables unbiased discovery of novel therapeutic targets.Targeting SEMA4A using an a
